Sean Deacon

2.8k total citations · 1 hit paper
19 papers, 2.1k citations indexed

About

Sean Deacon is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Sean Deacon has authored 19 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Cell Biology. Recurrent topics in Sean Deacon's work include Protein Kinase Regulation and GTPase Signaling (5 papers), Receptor Mechanisms and Signaling (5 papers) and Computational Drug Discovery Methods (3 papers). Sean Deacon is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (5 papers), Receptor Mechanisms and Signaling (5 papers) and Computational Drug Discovery Methods (3 papers). Sean Deacon collaborates with scholars based in United States, United Kingdom and Germany. Sean Deacon's co-authors include Jeffrey R. Peterson, Haiching Ma, Karthik Devarajan, Theonie Anastassiadis, Vladimir I. Gelfand, Anna S. Serpinskaya, Alexander Beeser, Ulrike Rennefahrt, Jonathan Chernoff and Kurumi Y. Horiuchi and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Cell Biology and Nature Biotechnology.

In The Last Decade

Sean Deacon

19 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

2011 698 citations Theonie Anastassiadis, Sean Deacon et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sean Deacon United States	12	1.5k	742	388	224	161	19	2.1k
Bertram Canagarajah United States	16	2.0k 1.3×	530 0.7×	255 0.7×	192 0.9×	160 1.0×	21	2.4k
Arvin C. Dar United States	18	1.7k 1.1×	606 0.8×	284 0.7×	193 0.9×	99 0.6×	29	2.4k
Alexey Rak Germany	24	1.7k 1.1×	1.1k 1.4×	206 0.5×	131 0.6×	112 0.7×	53	2.4k
Markus Boehm United States	25	1.7k 1.1×	748 1.0×	359 0.9×	150 0.7×	88 0.5×	55	2.5k
Ingrid Remy Canada	14	1.6k 1.1×	388 0.5×	300 0.8×	87 0.4×	173 1.1×	15	2.2k
Jiing‐Dwan Lee United States	21	2.1k 1.4×	450 0.6×	472 1.2×	134 0.6×	159 1.0×	26	2.7k
Andrei Khokhlatchev United States	16	2.3k 1.5×	832 1.1×	366 0.9×	98 0.4×	168 1.0×	20	2.7k
Jeffrey A. Ubersax United States	8	2.5k 1.6×	1.0k 1.4×	369 1.0×	71 0.3×	162 1.0×	9	3.1k
Marc R. Birtwistle United States	23	1.8k 1.2×	367 0.5×	400 1.0×	260 1.2×	129 0.8×	74	2.5k
Dominico Vigil United States	19	1.7k 1.1×	295 0.4×	396 1.0×	144 0.6×	61 0.4×	26	2.0k

Countries citing papers authored by Sean Deacon

Since Specialization

Citations

This map shows the geographic impact of Sean Deacon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sean Deacon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sean Deacon more than expected).

Fields of papers citing papers by Sean Deacon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sean Deacon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sean Deacon. The network helps show where Sean Deacon may publish in the future.

Co-authorship network of co-authors of Sean Deacon

This figure shows the co-authorship network connecting the top 25 collaborators of Sean Deacon. A scholar is included among the top collaborators of Sean Deacon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sean Deacon. Sean Deacon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Nii, Takenobu, Varun V. Prabhu, Vivian Ruvolo, et al.. (2019). Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia. 33(12). 2805–2816. 50 indexed citations

Prabhu, Varun V., Abed Rahman Kawakibi, Neel S. Madhukar, et al.. (2019). Abstract 2749: Defining structure activity relationships for GPCR engagement and anti-cancer efficacy of imipridone small molecules. 2749–2749. 1 indexed citations

Free, R. Benjamin, Varun V. Prabhu, Chidananda Sulli, et al.. (2019). EXTH-33. RECEPTOR PHARMACOLOGY OF ONC201: THE FIRST BITOPIC DRD2 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY. Neuro-Oncology. 21(Supplement_6). vi89–vi89. 1 indexed citations

Nii, Takenobu, Jo Ishizawa, Varun V. Prabhu, et al.. (2018). Abstract 4957: The novel imipridone ONC212 highly synergizes with the BCL-2 inhibitor ABT-199 in AML and activates orphan receptor GPR132. Cancer Research. 78(13_Supplement). 4957–4957. 4 indexed citations

Madhukar, Neel S., Varun V. Prabhu, Chidananda Sulli, et al.. (2017). EXTH-43. DIFFERENTIATED PHARMACOLOGY OF THE IMIPRIDONE ONC201, THE FIRST SELECTIVE DRD2/3 ANTAGONIST IN CLINICAL NEURO-ONCOLOGY. Neuro-Oncology. 19(suppl_6). vi81–vi82. 1 indexed citations

Prabhu, Varun V., Neel S. Madhukar, Rohinton S. Tarapore, et al.. (2017). Abstract 1155: Potent anti-cancer effects of selective GPR132/G2A agonist imipridone ONC212 in leukemia and lymphoma. Cancer Research. 77(13_Supplement). 1155–1155. 2 indexed citations

Beeharry, Neil, James C. Hittle, Vladimir Khazak, et al.. (2014). Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints. Cell Cycle. 13(14). 2172–2191. 11 indexed citations

Anastassiadis, Theonie, Krisna C. Duong‐Ly, Sean Deacon, et al.. (2013). A Highly Selective Dual Insulin Receptor (IR)/Insulin-like Growth Factor 1 Receptor (IGF-1R) Inhibitor Derived from an Extracellular Signal-regulated Kinase (ERK) Inhibitor. Journal of Biological Chemistry. 288(39). 28068–28077. 13 indexed citations

Beeharry, Neil, et al.. (2013). Abstract B57: Bosutinib and bosutinib-isomer are novel Chk1 and Wee1 kinase inhibitors that sensitize cells to DNA damaging agent by overriding cell cycle checkpoint arrest.. Molecular Cancer Therapeutics. 12(11_Supplement). B57–B57. 1 indexed citations

10.

Duong‐Ly, Krisna C., Theonie Anastassiadis, Sean Deacon, et al.. (2013). Abstract A291: A highly selective dual insulin receptor (IR)/insulin-like growth factor 1 receptor (IGF-1R) inhibitor derived from an ERK inhibitor.. Molecular Cancer Therapeutics. 12(11_Supplement). A291–A291. 1 indexed citations

11.

Anastassiadis, Theonie, Sean Deacon, Karthik Devarajan, Haiching Ma, & Jeffrey R. Peterson. (2011). Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nature Biotechnology. 29(11). 1039–1045. 698 indexed citations breakdown →

12.

Ma, Haiching, Sean Deacon, & Kurumi Y. Horiuchi. (2008). The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opinion on Drug Discovery. 3(6). 607–621. 161 indexed citations

13.

Deacon, Sean, Alexander Beeser, Jami Fukui, et al.. (2008). An Isoform-Selective, Small-Molecule Inhibitor Targets the Autoregulatory Mechanism of p21-Activated Kinase. Chemistry & Biology. 15(4). 322–331. 305 indexed citations

14.

Rennefahrt, Ulrike, Sean Deacon, Sirlester A. Parker, et al.. (2007). Specificity Profiling of Pak Kinases Allows Identification of Novel Phosphorylation Sites. Journal of Biological Chemistry. 282(21). 15667–15678. 108 indexed citations

15.

Eswaran, Jeyanthy, Wen‐Hwa Lee, J.E. Debreczeni, et al.. (2007). Crystal Structures of the p21-Activated Kinases PAK4, PAK5, and PAK6 Reveal Catalytic Domain Plasticity of Active Group II PAKs. Structure. 15(2). 201–213. 96 indexed citations

16.

Deacon, Sean, A A C Nascimento, Anna S. Serpinskaya, & Vladimir I. Gelfand. (2005). Regulation of Bidirectional Melanosome Transport by Organelle Bound MAP Kinase. Current Biology. 15(5). 459–463. 38 indexed citations

17.

Deacon, Sean, Anna S. Serpinskaya, Patricia S. Vaughan, et al.. (2003). Dynactin is required for bidirectional organelle transport. The Journal of Cell Biology. 160(3). 297–301. 258 indexed citations

18.

Gross, Steven P., M. Carolina Tuma, Sean Deacon, et al.. (2002). Interactions and regulation of molecular motors in Xenopus melanophores. The Journal of Cell Biology. 156(5). 855–865. 245 indexed citations

19.

Karcher, Ryan L., Sean Deacon, & Vladimir I. Gelfand. (2002). Motor–cargo interactions: the key to transport specificity. Trends in Cell Biology. 12(1). 21–27. 151 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact